5414x (2024)

: £12.9 million (+27.4%), supported by synthetic biology.

: Completed a programme resulting in an approximately 5% reduction in workforce to reallocate capital to growth areas. : £12

: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. : £12.9 million (+27.4%)

: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth : up 24% year-on-year. : 58.2%